3-hydroxyanthranilic acid has been researched along with Cognitive Decline in 2 studies
3-Hydroxyanthranilic Acid: An oxidation product of tryptophan metabolism. It may be a free radical scavenger and a carcinogen.
3-hydroxyanthranilic acid : An aminobenzoic acid that is benzoic acid substituted at C-2 by an amine group and at C-3 by a hydroxy group. It is an intermediate in the metabolism of the amino acid tryptophan.
3-hydroxyanthranilate : A hydroxybenzoate that is the conjugate base of 3-hydroxyanthranilic acid.
Excerpt | Relevance | Reference |
---|---|---|
" In individuals with prediabetes, 3-hydroxykynurenine (OR per SD 0." | 8.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
"Several kynurenines were cross-sectionally associated with lower odds of cognitive impairment and better cognitive functioning in type 2 diabetes, while less widespread associations were seen in prediabetes." | 8.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
"In individuals with type 2 diabetes, kynurenine (0." | 5.62 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
" In individuals with prediabetes, 3-hydroxykynurenine (OR per SD 0." | 4.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
"Several kynurenines were cross-sectionally associated with lower odds of cognitive impairment and better cognitive functioning in type 2 diabetes, while less widespread associations were seen in prediabetes." | 4.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
"Studies in Alzheimer's disease (AD) patients confirm KP dyshomeostasis in plasma and cerebrospinal fluid (CSF) which correlates with amyloid-β and tau pathology." | 1.72 | Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β. ( Bourgeat, P; Cespedes, M; Chatterjee, P; Doecke, JD; Fowler, CJ; Guillemin, GJ; Ittner, A; Jacobs, KR; Lim, CK; Lovejoy, DB; Martins, RN; Maruff, P; Masters, CL; Pertile, KK; Rainey-Smith, SR; Rembach, A; Rowe, CC; Rumble, RL; Trounson, B; Villemagne, VL, 2022) |
"In individuals with type 2 diabetes, kynurenine (0." | 1.62 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Cespedes, M | 1 |
Jacobs, KR | 1 |
Maruff, P | 1 |
Rembach, A | 1 |
Fowler, CJ | 1 |
Trounson, B | 1 |
Pertile, KK | 1 |
Rumble, RL | 1 |
Rainey-Smith, SR | 1 |
Rowe, CC | 1 |
Villemagne, VL | 1 |
Bourgeat, P | 1 |
Lim, CK | 1 |
Chatterjee, P | 1 |
Martins, RN | 1 |
Ittner, A | 1 |
Masters, CL | 1 |
Doecke, JD | 1 |
Guillemin, GJ | 1 |
Lovejoy, DB | 1 |
Bakker, L | 1 |
Ramakers, IHGB | 1 |
van Boxtel, MPJ | 1 |
Schram, MT | 1 |
Stehouwer, CDA | 1 |
van der Kallen, CJH | 1 |
Dagnelie, PC | 1 |
van Greevenbroek, MMJ | 1 |
Wesselius, A | 1 |
Midttun, Ø | 1 |
Ueland, PM | 1 |
Verhey, FRJ | 1 |
Eussen, SJPM | 1 |
Köhler, S | 1 |
2 other studies available for 3-hydroxyanthranilic acid and Cognitive Decline
Article | Year |
---|---|
Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β.
Topics: 3-Hydroxyanthranilic Acid; Alzheimer Disease; Amyloid beta-Peptides; Australia; Biomarkers; Cognitiv | 2022 |
Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study.
Topics: 3-Hydroxyanthranilic Acid; Aged; Biomarkers; Blood Glucose; Cognition; Cognitive Dysfunction; Cross- | 2021 |